(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 15.29% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Transmedics Group's revenue in 2025 is $566,354,000.On average, 16 Wall Street analysts forecast TMDX's revenue for 2025 to be $20,950,228,198, with the lowest TMDX revenue forecast at $20,061,012,262, and the highest TMDX revenue forecast at $21,702,063,348. On average, 16 Wall Street analysts forecast TMDX's revenue for 2026 to be $25,231,245,891, with the lowest TMDX revenue forecast at $23,001,371,185, and the highest TMDX revenue forecast at $27,052,395,670.
In 2027, TMDX is forecast to generate $29,692,362,276 in revenue, with the lowest revenue forecast at $26,491,253,254 and the highest revenue forecast at $32,524,388,589.